For job hunters CV and LinkedIn Coaching Reverse recruitment Students and academia Professionals and managers Directors and executives For employers Reviews Blog Guides Statutory roles Pharma ATS report Pharma jobs Arbeitszeugnis check Arbeitszeugnis decoder Pharma CV templates Pharma CV checker Interview ranking Job search statistics Notice period calculator Salary bands Job market pulse Hidden gem employers AI persona Newsletter About Book a free getting-to-know call
EN DE PL
← MoreThanCareer.de

Pharma R&D Jobs 2026: Discovery, Preclinical, Translational Research, Salary and Career in DACH

What does pharma R&D earn in DACH 2026?

Pharma R&D in DACH pays from postdoc (€60,000–75,000) to head of research (€220,000–320,000). Discovery research covers target identification, lead optimisation, medicinal chemistry, in vitro/in vivo pharmacology. Preclinical and translational research bridges to the clinic (PK/PD, toxicology, biomarkers). PhD is a prerequisite at 90%+ of senior roles. Highest-density locations: Basel (Roche, Novartis), Penzberg (Roche), Mannheim (Roche), Wuppertal (Bayer), Ingelheim (Boehringer), Darmstadt (Merck KGaA), Biberach (Boehringer), Berlin (Bayer Research), Mainz (BioNTech).

What pharma R&D actually covers

Pharma R&D divides into multiple phases with distinct functions and profiles. Discovery research: target identification (genomics, proteomics, AI/ML), target validation (CRISPR screens, knock-out models), lead identification (high-throughput screening, fragment-based drug discovery), lead optimisation (medicinal chemistry, structure-based drug design). Preclinical research: in vitro pharmacology, in vivo pharmacology, ADME (absorption, distribution, metabolism, excretion), pharmacokinetics / pharmacodynamics (PK/PD), toxicology (GLP), bioanalytics. Translational research: biomarker discovery, companion diagnostics, patient stratification, translational medicine. Computational R&D: bioinformatics, cheminformatics, AI/ML-based drug discovery, molecular modelling, systems biology. CMC development: formulation development, process development, analytical development, stability studies (at the interface to manufacturing).

Who hires pharma R&D in DACH

Big Pharma R&D hubs in DACH: Roche (Basel HQ, Penzberg, Mannheim), Novartis (Basel HQ, Wehr), Boehringer Ingelheim (Ingelheim, Biberach), Bayer (Berlin, Wuppertal, Leverkusen), Merck KGaA (Darmstadt), Sanofi (Frankfurt), AstraZeneca (Gothenburg, Cambridge plus DACH translational), GSK (Stevenage, Wavre plus DACH sites), Pfizer (Sandwich/UK, Cambridge/USA plus DACH affiliates). Specialty biotech: BioNTech (Mainz), Curevac (Tübingen), MorphoSys (Planegg/Munich), Evotec (Hamburg), Adagio Therapeutics, BioMed X (Heidelberg), Cardurion. Generics/biosimilar R&D: Hexal/Sandoz Biosimilar (Holzkirchen), Stada Specialty Pharma, Mylan/Viatris Biosimilar. CROs with R&D services: Evotec, Charles River Laboratories, Eurofins Discovery, Selvita, Sygnature Discovery, Aragen Bio. Academia-industry partnerships: Max Planck Institutes, Helmholtz Centres, EMBL Heidelberg, Charité Berlin (translational).

Pharma R&D salary bands DACH 2026

Industry postdoc €60,000–75,000. Junior scientist (PhD) €75,000–90,000, scientist II €90,000–110,000, senior scientist €110,000–135,000. Principal scientist €135,000–165,000. Group leader / lab head €165,000–205,000. Senior group leader / distinguished scientist €205,000–255,000. Department head (research) €230,000–290,000. Vice president research €280,000–380,000. Head of research (country or therapy area) €250,000–320,000. Global head of research €320,000–500,000+ plus significant stock awards. AI/ML in drug discovery, ATMP R&D (gene, cell therapy), oncology, and rare disease pay a 15–25% premium. Bonus 15–30%, stock awards / RSUs at US companies are standard.

The hidden R&D job market

Most junior scientist and scientist II roles are advertised (LinkedIn, Naturejobs, Sciencecareers, pharma career portals); across the German market, personal contacts decided 27 per cent of hires in 2025 (IAB-Stellenerhebung). For senior scientist and principal scientist, my estimate from 17 years of recruiting is that 60 to 70 per cent of roles are filled without a public advert, often through specialist headhunters (Quanta Consultancy, Real Staffing R&D, Hays Life Sciences R&D, ProClinical Science, Klein Hersh). Group leader and department head roles sit at the upper end of that range. Egon Zehnder, Russell Reynolds, Heidrick & Struggles, Spencer Stuart, Klein Hersh for senior executive search. Most VP research and global head research roles go without a public advert, mostly via executive search or direct network relationships. Hot areas with the highest hidden share: AI/ML in drug discovery, gene therapy, cell therapy, mRNA therapeutics, radiopharmaceuticals, antibody-drug conjugates.

Pharma R&D career paths in DACH

Standard academia-to-industry path: PhD (3–5 years) → postdoc (2–3 years industry or academia) → junior scientist pharma → scientist II (2–3 years) → senior scientist (3–5 years) → principal scientist or group leader → department head → VP research. Moves between R&D ↔ clinical development are standard in translational research and biomarker roles. AI/ML, bioinformatics, and computational R&D careers are shorter, with PhD plus 3–5 years of pharma experience, group leader roles are realistic. Specialty indications (oncology, rare disease, ATMP) and hot technology areas (AI/ML, radiopharmaceuticals, ADCs) accelerate careers significantly. My Reverse Recruitment covers roles in Germany: it helps plan academia-to-industry moves or specialty pivots precisely and builds the application for every role you green-light, which I submit in your name once you approve it. Whichever country the role is in, my service is application support only, not job placement and not a recruitment agency service (in German law: Arbeitsvermittlung and Personalvermittlung); you are the applicant and I contact no employer on your behalf. For roles outside Germany, Switzerland included, I work as your coach and you send every application yourself.

Frequently asked questions

Do I need a PhD for pharma R&D in DACH?

For discovery research, preclinical research, and translational research, a PhD is a prerequisite at 90%+ of senior roles. For CMC development (formulation, process, analytical), a master's with significant industry experience often suffices. For bioinformatics and computational drug discovery, a PhD is standard, but strong senior profiles with a master's plus 8–10 years of pharma AI experience can place into senior roles.

Which R&D specialisation has the best career growth in 2026?

AI/ML in drug discovery, ATMP R&D (gene, cell therapy, mRNA), radiopharmaceuticals, antibody-drug conjugates (ADCs), companion diagnostics, translational medicine for oncology and rare disease have the strongest growth in 2026. These specialty areas pay a 15–25% premium and accelerate career pace by 30–50%.

Is the move from academia into industry R&D realistic in DACH 2026?

Yes, especially with a PhD from DACH research institutions (Max Planck, Helmholtz, EMBL, ETH, university research) and 1–2 postdocs. Industry postdoc programmes at Roche, Novartis, Bayer, Boehringer, Merck, and BioNTech are common bridges. Important: targeted applications with a clear indication or technology specialisation, not generic academic profiles.

Want a clearer route to one of these roles?

Twenty minutes, no agenda, no pressure. I will tell you honestly which approach, CV rewrite, coaching, or full reverse recruitment, makes sense for your situation.

Book a free getting-to-know call